Continue now, decide again at two years: the NU675 Unit 2 paper's verdict for a composite young man after one severe psychotic episode, with reduction criteria set. Searches like "nu 675 unit 2 assignment example", "nu675 unit 2 sample" and "nu675 unit 2 example" land here.
What a finished NU675 Unit 2 continuation decision paper looks like
About five pages in four sections. The history section lists what the decision turns on: a single episode, but with command hallucinations, [16] days as an inpatient and insight that returned only after [six] weeks; daily cannabis use before onset, now [stopped]; an uncle with schizophrenia; and [8 kg] of weight gain with a flat, slowed feeling he dislikes. Three studies anchor the evidence section. Tiihonen and colleagues (2018) followed a Finnish first-episode cohort for twenty years and linked discontinuation with higher rehospitalization and mortality. Wunderink and colleagues (2013) found better seven-year functional recovery in a dose-reduction arm despite early relapses. The RADAR trial (Moncrieff et al., 2023) found more relapses with gradual reduction and no gain in social functioning at two years. The decision section and a short plan for side effects follow.
How a NU675 Unit 2 example is structured
The paper decides by weighing, and it shows the weights. A short table scores each factor as favoring continuation, favoring a trial reduction or neutral, and the prose explains the three that carry most: severity of the episode, the cannabis history and the side effects he reports. Studies are read for their populations before their results, so the paper notes that RADAR enrolled people with more than one episode and that Wunderink's benefit appeared only years after the relapses. His own reasons are quoted and treated as data about tolerability, which leads to a separate section on reducing the burden without stopping: exercise support, a weight plan with primary care and a review of dose. The decision is written with a review date, [month 24 of remission], and names the findings that would bring reduction forward or push it back.
Severity weighed with the count
One episode can still be a heavy one. Command hallucinations, a long admission and a slow return of insight are set against the fact that he has never relapsed, and the paper explains why those markers argue for caution despite the low count.
Cannabis as a relapse factor
Daily use before onset is recorded, along with evidence that continued cannabis use after a first episode is linked to relapse. His current abstinence counts in favor of eventual reduction, and a return to use is listed as a reason to hold.
Three studies, read by population
A registry cohort, a randomized reduction trial and a recent multi-episode trial each receive a paragraph that states who was studied before what was found. That order keeps a result from one population from being applied carelessly to another.
His reasons as tolerability data
Feeling flattened and the weight gain are taken as evidence that the current regimen costs him something real. The paper answers with changes that lower the cost without stopping, and records that he agreed to try them first.
A date for deciding again
Month twenty-four of remission is set as the next decision point, with criteria for a slow reduction then: sustained remission, no cannabis use, stable work and an agreed early-warning plan. Each criterion can be verified on the day itself.
Where marks go in NU675 Unit 2
A continuation decision is graded on whether it fits the history it rests on. Treating a first episode as automatically safe to stop, or as automatically lifelong, ignores the severity markers this case supplies, and either shortcut costs heavily. Citation accuracy draws close attention: describing RADAR as a first-episode study, or reporting Wunderink's recovery finding without the early relapses, misstates the evidence. A decision without a review date reads as open-ended, which graders tend to treat as no decision. Side effects mentioned and then left unaddressed signal that the patient's reasons were heard but not used. A paper that never mentions cannabis, when the case records daily use, has missed a relapse factor in plain sight. Brief comments go to unbracketed doses, an APA recommendation referenced with no date and no plan for monitoring during any reduction.
Get a NU675 Unit 2 example written to your instructions
Include the case from your NU675 Unit 2 prompt with every prior episode, admission and side effect it lists, plus the rubric; a continuation decision rests on that history. Your first custom paper is free, weighs each factor openly and fixes the next decision date, and it arrives within 24-48h.
NU675 Unit 2 questions, answered
Is a first episode always a reason to stop treatment sooner?
Not always. A single episode lowers one risk factor but says nothing about severity, insight, substance use or family history, each of which can argue for longer maintenance. Guidelines commonly recommend continuing antipsychotic treatment for a year or more after a first episode. Weigh the factors visibly and cite the guideline you rely on, with its year.
How should the paper use studies with conflicting results?
Describe each study's population and design before its result, then explain why their findings differ. Here a registry cohort, a trial with long follow-up and a recent multi-episode trial point in different directions partly because they asked different questions. Say which study resembles the patient most, and let that comparison, rather than the most convenient result, carry the argument.
Can a continuation paper recommend reducing the dose instead of stopping?
Yes, and many strong papers do, provided the reduction is gradual, monitored and tied to criteria. Say how the lowest effective dose would be approached, which early signs would halt it and who would notice them. Keep any figures bracketed as composite. A reduction written as a vague intention to lower the dose later earns little.